"They are casting the net as far and wide as possible so that approval can be sought in as many indications as possible"
Yes, and also so that payers will agree to pay for Zantrene (after it's approved for EMD AML) to be used off label in unapproved indications where a P2 has shown efficacy and safety.
I agree re the EM AML preclinical informing the CDx.
All the preclinicals will inform the CDx, because the same FTO assay may have different cutoff points for different cancers as to which patients would and would not benefit.
Ann: Race online Q&A investor briefing invitation, page-77
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
0.050(3.15%) |
Mkt cap ! $278.7M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.65 | $1.57 | $98.54K | 60.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2377 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 320 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |